New era of biologic therapeutics in atopic dermatitis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Atopic dermatitis (AD) is a common inflammatory skin disease regulated by genetic and environmental factors. Both skin barrier defects and aberrant immune responses are believed to drive cutaneous inflammation in AD. Existing therapies rely largely on allergen avoidance, emollients and topical and systemic immune-suppressants, some with significant toxicity and transient efficacy; no specific targeted therapies are in clinical use today. As our specific understanding of the immune and molecular pathways that cause different subsets of AD increases, a variety of experimental agents, particularly biologic agents that target pathogenic molecules bring the promise of safe and effective therapeutics for long-term use. AREAS COVERED: This paper discusses the molecular pathways characterizing AD, the contributions of barrier and immune abnormalities to its pathogenesis, and development of new treatments that target key molecules in these pathways. In this review, we will discuss a variety of biologic therapies that are in development or in clinical trials for AD, perhaps revolutionizing treatment of this disease. EXPERT OPINION: Biologic agents in moderate to severe AD offer promise for controlling a disease that currently lacks good and safe therapeutics posing a large unmet need. Unfortunately, existing treatments for AD aim to decrease cutaneous inflammation, but are not specific for the pathways driving this disease. An increasing understanding of the immune mechanisms underlying AD brings the promise of narrow targeted therapies as has occurred for psoriasis, another inflammatory skin disease, for which specific biologic agents have been demonstrated to both control the disease and prevent occurrence of new skin lesions. Although no biologic is yet approved for AD, these are exciting times for active therapeutic development in AD that might lead to revolutionary therapeutics for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 15×
“Numbers of Th22 cells, which produce IL-22, are increased in patients with chronic AD, and mRNA expression of the IL-22 cytokine and its induced factors are also increased in acute AD [123,124,127,128], indicating that that IL-22 might be a therapeutic target for patients with AD.”
BackgroundInfluentialEndogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960 · cited 2×
“4 Paving the path for future therapeutic development in AD Several clinical trials with broad T-cell targeting therapeutics such as cyclosporine (CsA) [64-68], Alefacept [66,68], and efalizumab [67,69], found clinical benefit in patients with moderate to severe AD.”
BackgroundSelf-citationNew insights into atopic dermatitis
Leung, D. Y. M., Boguniewicz, M., Howell, M. D., Nomura, I., & Hamid, Q. A. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21060 · Cited by 1,435
Self-citationInterleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409 · cited 3×
“Although previously characterized as Th1 vs Th2 T-cell polarized diseases, these conditions have recently also been demonstrated to exhibit distinct differential expression of the newly described Th17 and Th22 T-cell subsets [10,11].”
BackgroundAtopic dermatitis and the atopic march
Spergel, J. M., & Paller, A. S. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.033 · Cited by 1,229 · cited 1×
“Together with asthma and allergic rhinitis, it constitutes the “atopic triad” [4].”
BackgroundFilaggrin Mutations Associated with Skin and Allergic Diseases
Irvine, A. D., McLean, W. H. I., & Leung, D. Y. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011040 · Cited by 1,217 · cited 3×
“Between 10 and 50% (depending on population) of the AD patients have been reported to have FLG mutations [41,42].”
BackgroundSelf-citationPPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells
Cipolletta, D., Feuerer, M., Li, A., Kamei, N., Lee, J., Shoelson, S. E., Benoist, C., & Mathis, D. (2012) · Nature · doi:10.1038/nature11132 · Cited by 1,143 · cited 2×
“7 Peroxisome proliferator-activated receptor gamma (PPAR-g) agonists (Thiazolidinediones) Thiazolidinediones activate the nuclear receptor, PPAR-g , which is expressed on adipocytes and immune cells [145-154].”
BackgroundChawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 2×
“7 Peroxisome proliferator-activated receptor gamma (PPAR-g) agonists (Thiazolidinediones) Thiazolidinediones activate the nuclear receptor, PPAR-g , which is expressed on adipocytes and immune cells [145-154].”
BackgroundBoniface, K., Bernard, F.-X., Garcia, M., Gurney, A. L., Lecron, J.-C., & Morel, F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3695 · Cited by 864
Peroxisome proliferator-activated receptors in inflammation control
Delerive, P., Fruchart, J., & Staels, B. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690453 · Cited by 755 · cited 2×
“7 Peroxisome proliferator-activated receptor gamma (PPAR-g) agonists (Thiazolidinediones) Thiazolidinediones activate the nuclear receptor, PPAR-g , which is expressed on adipocytes and immune cells [145-154].”
Background
Cited by
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697
Self-citationThe immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Self-citationConjunctivitis in dupilumab clinical trials
Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E. L., Blauvelt, A., Cork, M. J., Prens, E., Asbell, P., Akpek, E., Corren, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17869 · Cited by 442
Self-citationAtopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
Boguniewicz, M., Fonacier, L., Guttman-Yassky, E., Ong, P. Y., Silverberg, J., & Farrar, J. R. (2018) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2017.10.039 · Cited by 305
Self-citationGuttman-Yassky, E., Pavel, A. B., Zhou, L., Estrada, Y. D., Zhang, N., Xu, H., Peng, X., Wen, H.-C., Govas, P., Gudi, G., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.053 · Cited by 220
Self-citation
Metadata
- Authors
- Guttman-Yassky, E., Dhingra, N., & Leung, D. Y.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-01-16
- Volume
- 13
- Issue
- 4
- Pages
- 549-561
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2048138796
- Cited by
- 104
- References
- 25
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New era of biologic therapeutics in atopic dermatitis. https://app.cochat.ai/papers/10.1517/14712598.2013.758708
- The paper
- Guttman-Yassky, E., Dhingra, N., & Leung, D. Y. (2013). New era of biologic therapeutics in atopic dermatitis. Expert Opinion on Biological Therapy. https://doi.org/10.1517/14712598.2013.758708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.